GILD · Gilead Sciences, Inc.
$129.35
-1.51 (-1.15%)
At close · Jul 24
Market Cap
$160.55B
Shares
1.24B
Gilead Sciences, Inc. Earnings Call Transcripts
Every quarterly earnings call for Gilead Sciences, Inc. (GILD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼5.1%
$7.04B
$1.79B
'22 Q3
22-10-27
▲2%
$7.39B
$1.64B
'22 Q4
23-02-02
▼3.6%
$6.35B
$1.01B
'23 Q1
23-04-27
▲5.4%
$6.60B
$1.04B
'23 Q2
23-08-03
▲0.1%
$7.05B
$2.18B
'23 Q3
23-11-07
▼3.7%
$7.11B
$1.43B
'23 Q4
24-02-06
▲5.3%
$6.69B
−$4.17B
'24 Q1
24-04-25
▲5.4%
$6.95B
$1.61B
'24 Q2
24-08-08
▲7%
$7.54B
$1.25B
'24 Q3
24-11-06
▲6.4%
$7.57B
$1.78B
'24 Q4
25-02-11
▼0.3%
$6.67B
$1.31B
'25 Q1
25-04-24
▲1.8%
$7.08B
$1.96B
'25 Q2
25-08-07
▲3%
$7.77B
$3.05B
'25 Q3
25-10-30
▲4.7%
$7.92B
$2.18B
'25 Q4
26-02-10
LATEST
▲4.4%
$6.96B
$2.02B
'26 Q1
26-05-07
Earnings call
FY26 · Q2
2026-08-04
Gilead Sciences Q2 2026 Earnings Conference Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-28
Bernstein’s Annual Strategic Decisions Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Gilead Sciences, Inc. Q1 FY2026 Earnings Call
Confident tone
HIV franchise growth and pipeline
Cell therapy and anitocel launch
Business development and acquisitions
Revenue
$6.96B
▲ 4.4% YoY Diluted EPS
$1.61
▲ 54.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Barclays Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-10
Leerink Partners Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-03
TD Cowen Annual Health Care Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-10
Gilead Sciences, Inc. Q4 FY2025 Earnings Call
Confident tone
HIV business growth and Biktarvy
YES2GO HIV prevention launch
Oncology and Trodelvy expansion
Revenue
$7.92B*
▲ 4.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
J.P. Morgan Annual Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-11-19
Jefferies Global Healthcare Conference in London
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-30
Gilead Sciences, Inc. Q3 FY2025 Earnings Call
Confident tone
HIV franchise growth
Yeztugo launch
Oncology pipeline
Revenue
$7.77B
▲ 3% YoY Diluted EPS
$2.43
▲ 143% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Gilead Sciences, Inc. Q2 FY2025 Earnings Call
Confident tone
HIV franchise performance
Yeztugo (lenacapavir) launch
Trodelvy in metastatic TNBC
Revenue
$7.08B
▲ 1.8% YoY Diluted EPS
$1.56
▲ 20.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
Gilead Sciences, Inc. Q1 FY2025 Earnings Call
Confident tone
HIV franchise and Biktarvy growth
Lenacapavir for PrEP launch
Trodelvy and oncology pipeline
Revenue
$6.67B
▼ 0.3% YoY Diluted EPS
$1.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Gilead Sciences, Inc. Q4 FY2024 Earnings Call
Confident tone
HIV franchise growth and leadership
Lenacapavir for HIV prevention
Pipeline depth and long-term growth outlook
Revenue
$7.57B*
▲ 6.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Gilead Sciences, Inc. Q3 FY2024 Earnings Call
Confident tone
Lenacapavir for HIV PrEP
Oncology and cell therapy
HIV franchise performance
Revenue
$7.54B
▲ 7% YoY Diluted EPS
$1.00
▼ 42.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Gilead Sciences, Inc. Q2 FY2024 Earnings Call
Confident tone
HIV prevention (lenacapavir / PURPOSE)
Oncology - Trodelvy
Long-acting HIV pipeline
Revenue
$6.95B
▲ 5.4% YoY Diluted EPS
$1.29
▲ 55.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Gilead Sciences, Inc. Q1 FY2024 Earnings Call
Confident tone
HIV franchise performance and growth
Liver disease and Celadelpar
Trodelvy and oncology
Revenue
$6.69B
▲ 5.3% YoY Diluted EPS
$-3.34
▼ 517.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-06
Gilead Sciences, Inc. Q4 FY2023 Earnings Call
Positive tone
Oncology portfolio expansion
Trodelvi EVOKE-01 trial outcome
2024 clinical catalysts and pipeline updates
Revenue
$7.11B*
▼ 3.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Gilead Sciences, Inc. Q3 FY2023 Earnings Call
Revenue
$7.05B
▲ 0.1% YoY Diluted EPS
$1.73
▲ 21.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Gilead Sciences, Inc. Q2 FY2023 Earnings Call
Revenue
$6.60B
▲ 5.4% YoY Diluted EPS
$0.83
▼ 8.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Gilead Sciences, Inc. Q1 FY2023 Earnings Call
Revenue
$6.35B
▼ 3.6% YoY Diluted EPS
$0.80
▲ 3900% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-02
Gilead Sciences, Inc. Q4 FY2022 Earnings Call
Revenue
$7.39B*
▲ 2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Gilead Sciences, Inc. Q3 FY2022 Earnings Call
Revenue
$7.04B
▼ 5.1% YoY Diluted EPS
$1.42
▼ 30.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Gilead Sciences, Inc. Q2 FY2022 Earnings Call
Revenue
$6.26B
▲ 0.7% YoY Diluted EPS
$0.91
▼ 24.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Gilead Sciences, Inc. Q1 FY2022 Earnings Call
Revenue
$6.59B
▲ 2.6% YoY Diluted EPS
$0.02
▼ 98.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-01
Gilead Sciences, Inc. Q4 FY2021 Earnings Call
Revenue
$7.24B*
▼ 2.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Gilead Sciences, Inc. Q3 FY2021 Earnings Call
Revenue
$7.42B
▲ 12.8% YoY Diluted EPS
$2.05
▲ 606.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Gilead Sciences, Inc. Q2 FY2021 Earnings Call
Revenue
$6.22B
▲ 20.9% YoY Diluted EPS
$1.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Gilead Sciences, Inc. Q1 FY2021 Earnings Call
Revenue
$6.42B
▲ 15.8% YoY Diluted EPS
$1.37
▲ 12.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-04
Gilead Sciences, Inc. Q4 FY2020 Earnings Call
Revenue
$7.42B
▲ 26.2% YoY Diluted EPS
$1.23
▼ 42% YoY Gross margin
79.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Gilead Sciences, Inc. Q3 FY2020 Earnings Call
Revenue
$6.58B
▲ 17.4% YoY Diluted EPS
$0.29
Gross margin
81.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Gilead Sciences, Inc. Q2 FY2020 Earnings Call
Revenue
$5.14B
▼ 9.5% YoY Diluted EPS
$-2.66
▼ 281% YoY Gross margin
77.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Gilead Sciences, Inc. Q1 FY2020 Earnings Call
Revenue
$5.55B
▲ 5.1% YoY Diluted EPS
$1.22
▼ 20.8% YoY Gross margin
81.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-04
Gilead Sciences, Inc. Q4 FY2019 Earnings Call
Revenue
$5.88B
▲ 1.4% YoY Diluted EPS
$2.12
Gross margin
70.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–34 of 34 earnings calls
Key facts
CIK
882095
CUSIP
375558103
13F (30d)
731 filings
698 filers
Visit website
Investor relations